Skip links

“Not just GenAI” Leadership Series — Part II

Jump To Section

“Not just GenAI” Leadership Series — Part II

This is part of a series of bite sized quick-reads that will equip leadership levels with the requisite information around GenAI and related areas, enabling you to question proposals and make more informed decisions around such investments. 

These posts will take a balanced approach — talking about not just the strengths of these technologies, but also areas to watch out for. These topics would intentionally be presented in a simple discussion-like manner, rather than a dry/abstract third-party tone…Let’s dive in.

“How to find enterprise use cases that can leverage GenAI?”

The above question would be akin to asking,” What problems can I solve with a screwdriver?” rather than asking, “What are the prioritized list of problems that need to be solved, regardless of whether you use a screwdriver or a hammer or something else for the solution?”

Why look for use cases that leverage GenAI? Why not prioritize your business problems first, and then, if some of those problems can be solved by GenAI, so be it.

This is not just theoretical semantics. It’s a fundamentally incorrect way GenAI is being approached in an alarmingly large number organizations, that can lead to misplaced investments. 

Yes, GenAI is powerful, but it is not a panacea. It’s just one part of a bouquet of Digital Business components that can work together to elevate your business, provided the time-tested business principles are adhered to.

“If a business problem is already defined and prioritized, how does one check if GenAI is an appropriate solution for that?”

Now that’s a good question. You wouldn’t want to start with GenAI as the solution option. First of all, check if regular business rules can solve the problem. Such rules are deterministic. Meaning, you can predict their behaviour. You know what to expect, because you (and not the machine) defined those business rules. 

So, if business rules can solve the problem at hand, look no further.

Having said that, there may be problems where such deterministic rules may not work. This could be  because you do not know what rules will work. Or, it could be because the underlying business and data conditions change so rapidly that the rules defined today could get obsolete very quickly.

In such situations, the next best option is to look for applying Machine Learning (ML) techniques – either Discriminative or Generative. A gist of the 2 approaches is given below, but more details are presented in Part-I of this series.

Discriminative AI/ML is generally a better option, if:

  • The data is structured, meaning, it is available in rows and columns (like an Excel sheet)
  • There is not much ‘free text’ in the data, like language sentences.
  • You have a fairly large number of rows, the larger the better.
  • The problem is a supervised one (details below)

Note: If there is a non-trivial amount of free text in the data, then you’d need to convert that into structured, using a GenAI technique.

Generative AI/ML is generally a better option, if:

  • The data is unstructured, in the form of text, images etc.
  • The data is structured, but you have a small number of rows
  • It’s an unsupervised problem (details below)


  1. When the number of rows is less, Discriminative AI/ML struggles to give good results. GenAI is better in this case. 
  2. When the number of rows is more, then Discriminative is normally better than Generative.
  3. The above points are general guidelines, and not absolute rules. For example, there are instances where you would prefer to use GenAI for Supervised learning.

Supervised, unsupervised and semi-supervised learning

In the above section, we saw references to these terms. Here, we’ll take a quick look at what they mean.

Supervised Learning

You are the Head of the GRC (Governance, Risk and Compliance) team at a leading Bank. Your team has collected historical data about credit card defaults in the past. It’s a good set of data, which contains information about not just defaulters, but also non-defaulters. Every entry/row has variables like employment status, age, gender, credit card limit etc, and the corresponding value of ‘defaulter or non-defaulter’. This last value is called the target variable. This is what you need to predict, when a new applicant comes in.

Your Data Science team applies algorithms to build models which try to correlate the other variables with the target variable. In other words, this target variable belonging to the historical data acts as a supervising element in the Machine learning process. Hence the term, supervised learning.

Here’s another (very important) way to look at it. The Machine Learning algorithm’s job is to find out probability of the person being a defaulter, given the other variables. 

This is denoted as P(Defaulter|x), where ‘x’ is the full set of variable values for that row.

This is called Conditional Probability, and is the fundamental identifier of a Discriminant AI/ML approach.

Unsupervised Learning

In these types of use cases, there is no target variable. Hence, Unsupervised. The job of the algorithms in this group, is to find patterns in the data. Clustering is a good example of Unsupervised learning. Again, note that clustering is not done basis any target variable. As with supervised algorithms, there are various techniques/algorithms for clustering, but the common job for all of them is to look at the data and break that into clusters. 

Clustering is just one example of Unsupervised algorithms. Another good example is this — you want the algorithm to look at some images and create more like those, within the bounds of the current set of images. For e.g., if the current set of images are human faces, then the ears of the new set of images should be within the bounds of regular human ears…the algorithm should not put elephant-size ears on a human face. This is where a good GenAI algo, which studies the probability distribution of each variable (e.g. ears) in the current data, and uses those bounds to create new data, shines. Discriminative AI/ML does not have this capability.

So, an Unsupervised algorithm’s priority is not Conditional Probability. Note that there is no target variable.

Semi-supervised learning

This is like a combination of the above 2 — a small set of labelled data (with target variable) is provided for Supervised learning. Also, there is a larger data set without labels (target variable) where the algorithm needs to learn like in the Unsupervised approach. 

GenAI algorithms normally fit well into the Un/Semi Supervised realm.


Naïve Bayes is an example of GenAI. It was introduced in 1960, about 60 years back.

Naïve Bayes, and GenAI in general, is founded on Bayes Theorem, stated about 250 years back.

So, no, GenAI is not new! It has made an impact recently due a perfect storm of various factors — Transformer architecture (the ‘T’ in GPT), availability of an unprecedented amount of data, large GPU farms etc.

This post gives an under-the-hood understanding of why GenAI is just one part of the overall AI umbrella. 
It is neither the ‘next version’ of AI superseding all before it, nor a ‘one size fits all’ solution. 
It’s just one more weapon in your AI repertoire, albeit a solid one if used judiciously, for solving business problems.
Picture of Jayaprakash Nair

Jayaprakash Nair

Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Michael Woodall

Chief Growth Officer of Financial Services

Michael Woodall, as the Chief Growth Officer of Financial Services at Altimetrik, spearheads the identification of new growth avenues and revenue streams within the financial services sector. With a robust background and extensive expertise, Michael brings invaluable insights to his role.

Previously, Michael served as the Chief of Operations and President of the Trust Company at Putnam Investments, where he orchestrated strategic developments and continuous operational enhancements. Leveraging strategic partnerships and data analytics, he revolutionized capabilities across investments, retail and institutional distribution, and client services. Under his leadership, Putnam received numerous accolades, including the DALBAR Mutual Fund Service Award for over 30 consecutive years.

Michael’s dedication to industry evolution is evident through his involvement with prestigious organizations such as the DTCC Senior Wealth Advisory Board, ICI Operations Committee, and NICSA, where he served as Chairman and now holds the position of Director Emeritus. Widely recognized as an industry luminary, Michael frequently shares his expertise with various divisions of the SEC, solidifying his reputation as a seasoned presenter.

At Altimetrik, Michael plays a pivotal role in driving expansion within financial services, leveraging his expertise and Altimetrik’s Digital Business Methodology to ensure clients navigate their digital journey seamlessly, achieving tangible outcomes and exponential growth.

Beyond his corporate roles, Michael serves as Chair of the Boston Water & Sewer Commission, appointed by the Mayor of Boston, and is actively involved in various philanthropic endeavors, including serving on the board of the nonprofit Inspire Arts & Music.

Michael holds a distinguished business degree from Northeastern University, graduating with distinction as a member of the Sigma Epsilon Rho Honor Society.

Anguraj Kumar Arumugam

Chief Digital Business Officer for the U.S. West region

Anguraj is an accomplished business executive with an extensive leadership experience in the services industry and strong background across digital transformation, engineering services, data and analytics, cloud and consulting.

Prior to joining Altimetrik, Anguraj has served in various positions and roles at Globant, GlobalLogic, Wipro and TechMahindra. Over his 25 years career, he has led many strategic and large-scale digital engineering and transformation programs for some of world’s best-known brands. His clients represent a range of industry sectors including Automotive, Technology and Software Platforms. Anguraj has built and guided all-star teams throughout his tenure, bringing together the best of the techno-functional capabilities to address critical client challenges and deliver value.

Anguraj holds a bachelor’s degree in mechanical engineering from Anna University and a master’s degree in software systems from Birla Institute of Technology, Pilani.

In his spare time, he enjoys long walks, hiking, gardening, and listening to music.

Vikas Krishan

Chief Digital Business Officer and Head of the EMEA region

Vikas (Vik) Krishan serves as the Chief Digital Business Officer and Head of the EMEA region for Altimetrik. He is responsible for leading and growing the company’s presence across new and existing client relationships within the region.

Vik is a seasoned executive and brings over 25 years of global experience in Financial Services, Digital, Management Consulting, Pre- and Post-deal services and large/ strategic transformational programmes, gained in a variety of senior global leadership roles at firms such as Globant, HCL, Wipro, Logica and EDS and started his career within Investment Banking. He has developed significant cross industry experience across a wide variety of verticals, with a particular focus on working with and advising the C-Suite of Financial Institutions, Private Equity firms and FinTech’s on strategy and growth, operational excellence, performance improvement and digital adoption.

He has served as the engagement lead on multiple global transactions to enable the orchestration of business, technology, and operational change to drive growth and client retention.

Vik, who is based in London, serves as a trustee for the Burma Star Memorial Fund, is a keen photographer and an avid sportsman.

Megan Farrell Herrmanns

Chief Digital Officer, US Central

Megan is a senior business executive with a passion for empowering customers to reach their highest potential. She has depth and breadth of experience working across large enterprise and commercial customers, and across technical and industry domains. With a track record of driving measurable results, she develops trusted relationships with client executives to drive organizational growth, unlock business value, and internalize the use of digital business as a differentiator.

At Altimetrik, Megan is responsible for expanding client relationships and developing new business opportunities in the US Central region. Her focus is on digital business and utilizing her experience to create high growth opportunities for clients. Moreover, she leads the company’s efforts in cultivating and enhancing our partnership with Salesforce, strategically positioning our business to capitalize on new business opportunities.

Prior to Altimetrik, Megan spent 10 years leading Customer Success at Salesforce, helping customers maximize the value of their investments across their technology stack. Prior to Salesforce, Megan spent over 15 years with Accenture, leading large transformational projects for enterprise customers.

Megan earned a Bachelor of Science in Mechanical Engineering from Marquette University. Beyond work, Megan enjoys playing sand volleyball, traveling, watching her kids soccer games, and is actively involved in a philanthropy (Advisory Council for Cradles to Crayons).

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes